Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day: Report on use of CD19 CAR T-cells in transformed Waldenström macroglobulinemia shows estimated PFS rates at 1 and 2 years were 73.4% and 67.5%, respectively, while estimated OS at 1 and 2 years were 80.5% and 69.5% (95% CI, 44.6-85.3).”
Proceed to the article.
Source: Robert Orlowski/X